G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis

[1]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[2]  James D. Robinson,et al.  G protein-coupled receptor kinase 2 (GRK2) is a Rho-activated scaffold protein for the ERK MAP kinase cascade. , 2013, Cellular signalling.

[3]  S. Loi,et al.  Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. , 2013, Cancer treatment reviews.

[4]  G. Dorn,et al.  Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. , 2013, The Journal of clinical investigation.

[5]  Jeffrey W. Peng,et al.  Interdomain Interactions Support Interdomain Communication in Human Pin1 , 2013, Biochemistry.

[6]  J. Renoir,et al.  Estrogen receptor signaling as a target for novel breast cancer therapeutics. , 2013, Biochemical pharmacology.

[7]  A. Giordano,et al.  The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast Cancer , 2013, PloS one.

[8]  S. Kwon,et al.  Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes , 2012, The FEBS journal.

[9]  V. Lafarga,et al.  The interplay between G protein-coupled receptor kinase 2 (GRK2) and histone deacetylase 6 (HDAC6) at the crossroads of epithelial cell motility , 2012, Cell adhesion & migration.

[10]  Ana Lluch,et al.  Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. , 2012, Cancer treatment reviews.

[11]  C. Brandl,et al.  Non-catalytic participation of the Pin1 peptidyl-prolyl isomerase domain in target binding , 2012, Front. Physio..

[12]  J. Engele,et al.  Grk2 is an Essential Regulator of CXCR7 Signalling in Astrocytes , 2012, Cellular and Molecular Neurobiology.

[13]  Y. Onodera,et al.  ['Molecular biology' of breast cancer]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[14]  L. Rhodes,et al.  Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat , 2012, Breast Cancer Research.

[15]  K. Lorenz,et al.  Raf Kinase Inhibitor Protein (RKIP) Dimer Formation Controls Its Target Switch from Raf1 to G Protein-coupled Receptor Kinase (GRK) 2* , 2012, The Journal of Biological Chemistry.

[16]  T. Daigle,et al.  GRK2: multiple roles beyond G protein-coupled receptor desensitization. , 2012, Trends in pharmacological sciences.

[17]  V. Lafarga,et al.  A novel GRK2/HDAC6 interaction modulates cell spreading and motility , 2012, The EMBO journal.

[18]  U. Moll,et al.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis , 2011, Cell Death and Differentiation.

[19]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[20]  Y. Liou,et al.  Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. , 2011, Trends in biochemical sciences.

[21]  Antonio Rosato,et al.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. , 2011, Cancer cell.

[22]  T. Hupp,et al.  How phosphorylation controls p53 , 2011, Cell cycle.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  Cristina Murga,et al.  The complex G protein‐coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets , 2010, British journal of pharmacology.

[25]  P. Khanal,et al.  The Prolyl Isomerase Pin1 Enhances HER-2 Expression and Cellular Transformation via Its Interaction with Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase 1 , 2010, Molecular Cancer Therapeutics.

[26]  T. Yao,et al.  The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation* , 2010, The Journal of Biological Chemistry.

[27]  Verónica Rivas,et al.  G protein–coupled receptor kinase 2 (GRK2) modulation and cell cycle progression , 2009, Proceedings of the National Academy of Sciences.

[28]  Y. Kalaidzidis,et al.  Regulation of Epidermal Growth Factor Receptor Trafficking by Lysine Deacetylase HDAC6 , 2009, Science Signaling.

[29]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[30]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[31]  K. Chin,et al.  Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression , 2009, Clinical Cancer Research.

[32]  Miou Zhou,et al.  17β-Estradiol-Mediated Neuroprotection and ERK Activation Require a Pertussis Toxin-Sensitive Mechanism Involving GRK2 and β-Arrestin-1 , 2009, The Journal of Neuroscience.

[33]  K. Horie-Inoue,et al.  Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. , 2009, Cancer research.

[34]  Mads Thomassen,et al.  Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer , 2008, BMC Cancer.

[35]  M. Caron,et al.  Smoothened signaling in vertebrates is facilitated by a G protein-coupled receptor kinase. , 2008, Molecular biology of the cell.

[36]  Xiao-Fan Wang,et al.  The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. , 2008, Cancer research.

[37]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[38]  O. Barreiro,et al.  G protein‐coupled receptor kinase 2 positively regulates epithelial cell migration , 2008, The EMBO journal.

[39]  E. Rozengurt.  Mitogenic signaling pathways induced by G protein‐coupled receptors , 2007, Journal of cellular physiology.

[40]  J. Rosen,et al.  Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.

[41]  J. Leal,et al.  Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. , 2007, Carcinogenesis.

[42]  R. Gainetdinov,et al.  Physiological roles of G protein-coupled receptor kinases and arrestins. , 2007, Annual review of physiology.

[43]  P. Penela,et al.  Mdm2 is involved in the ubiquitination and degradation of G‐protein‐coupled receptor kinase 2 , 2006, The EMBO journal.

[44]  Priti Garg,et al.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.

[45]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[46]  K. Lu.  Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. , 2003, Cancer cell.

[47]  A. Ryo,et al.  Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer , 2003, Journal of Cell Science.

[48]  Sam W. Lee,et al.  PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells , 2002, Molecular and Cellular Biology.

[49]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[50]  Jeffrey A. Jones,et al.  Gene targeting in ischemic heart disease and failure: translational and clinical studies. , 2013, Biochemical pharmacology.

[51]  Virginia Espina,et al.  Molecular Profiling , 2012, Methods in Molecular Biology.

[52]  M. Maggiolini,et al.  G protein-coupled receptors: novel targets for drug discovery in cancer , 2010, Nature Reviews Drug Discovery.